Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer |
| |
| Authors: | Sara López-Tarruella Miguel Martín |
| |
| Affiliation: | 1. Medical Oncology Department, Clínico San Carlos Hospital, Madrid, Profesor Martín Lagos, 28040, Madrid, Spain
|
| |
| Abstract: | Adjuvant treatment for early breast cancer is an evolving field. Since the advent of the initial cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimens, which reduced risk for recurrence and death, anthracyclines and subsequently taxanes were added to the cytotoxic armamentarium for use sequentially or in combination in the adjuvant setting. The efficacy and toxicity of each chemotherapy regimen must be viewed within the context of host co-morbidities and the specific biologic phenotype of the tumor. In the era of mammographic screening, small, node-negative breast cancer is the most frequent presentation of the disease. Patient selection for adjuvant chemotherapy has become a key issue. Traditional prognostic factors continue to be of value in determining the risk for relapse, but new and sophisticated genomic tools (such as Oncotype Dx® and Mammaprint®) are now available and may improve our ability to select patients. For those patients who do require adjuvant chemotherapy, the 'one size fits all' paradigm should never again feature in the treatment of early breast cancer, following the important insights yielded by biomarker research to identify those who will benefit the most from a particular drug. In this review we focus on some of the current controversies and potential future steps in adjuvant chemotherapy for treatment of early breast cancer. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
